On October 31, 2023, the New York State Department of Financial Services (DFS) released a notice of withdrawal for its previously proposed market conduct rules for pharmacy benefit managers (PBMs). The rules, which were initially announced on August 16, 2023, had aimed to enhance the state’s regulatory powers over PBMs significantly. However, in a surprising move, the state agency decided to withdraw these proposals.
This does not mean that the industry was left without changes. The DFS went ahead to finalize licensure rules for PBMs, which took effect on November 15, 2023. These decisions marked a significant shift in the regulatory landscape governing PBMs, potentially affecting operations and compliance for many businesses in the industry.
The initial proposed rules were geared at increasing the state’s oversight of PBMs, an aspect of operations that many industry stakeholders had held reservations about. Questions and debates have been a constant around the level and type of regulation PBMs ought to be subjected to. With the withdrawal of the proposed rule changes, businesses and stakeholders alike are left to ponder what this move could mean for the industry’s regulatory future. Instead of dealing with a possibly stricter environment, PBMs may now focus their efforts on meeting the requirements set out by the new licensure rules implemented by the DFS.
These changes come in the wake of increasing calls for transparency and tighter control over PBMs. While New York’s latest decision might seem like a step back from significantly enhanced oversight, the new licensure rules may carry implications themselves, impacting the terms upon which businesses operate in the industry.
You may find a deeper analysis of this regulatory shift on
JD Supra’s website.
In the coming days and weeks, it will be certainly interesting to follow how the industry will respond to the new set of rules and what impact this will have on the cost, quality, and access to health care services.